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Summary Statement: (Wordcount: 40) 
Short foveal fluorescence lifetimes are associated with foveal sparing (FS) and correlate with  
visual function. However, they are not an exclusive feature of FS and can occur in geographic 
atrophy without FS, presumably due to macular pigment r tention. 
 
This is an open-access article distributed under the terms of the Creative Commons 
Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is 
permissible to download and share the work provided t is properly cited. The work cannot be 
changed in any way or used commercially without permission from the journal. 
 
 
Abstract (Wordcount: 267) 
 
Purpose: Short foveal fluorescence lifetimes (fFLT) in geographic atrophy are typically 
found in eyes with foveal sparing (FS) but may also occur in eyes without FS. We 
investigated whether short fFLT could serve as a functional biomarker for disease 
progression in geographic atrophy (GA). 
Methods: Thirty three eyes were followed over the course of 4-6 years. FS was assessed 
using fluorescence lifetime imaging ophthalmoscopy, OCT, FAF and macular pigment 
optical density.  
Results: Eyes with FS exhibited shorter fFLT compared to eyes without FS. Short fFLT 
(<600ps) were measured in all eyes with FS and half of the eyes without FS. Eyes with FS 
showed a bigger increase in fFLT per year (+39/+30 ps (SSC/LSC) in FS vs. +29/+22 ps 
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SSC/LSC). MPOD measurements correlated significantly with fFLT but not in all spectral 
channels (p ranging from 0.018 to 0.077). 
Conclusion: In GA, shorter fFLT are associated with foveal sparing but they can also be 
observed in eyes without FS.  Our longitudinal data suggests that shorter fFLT features in 
eyes with loss of FS represent an earlier stage of disease and may be more prone to loss of 
visualacuity. 
Keywords: 
AMD, fluorescence lifetimes, fundus autofluorescence, FLIO, foveal sparing, geographic 
atrophy, retinal imaging  
 




Geographic atrophy (GA) due to age-related macular degeneration (AMD) is a progressive 
retinal disease, in which the retinal pigment epithel um and its over- and underlying 
structures, the outer retinal layers and the choroid, are mainly effected.1, 2 It can lead to a 
severe loss in visual acuity, especially in cases in which the fovea is affected.3 Various 
patterns of progression have been described. The causes leading to a specific pattern are 
unclear but they might have a prognostic value.4, 5 In some patients, the central part of the 
macula including the fovea are spared from atrophy for a long time compared to other 
patients in which this central region is affected at e rly stages of the disease.6 Involvement of 
the fovea seems to be dependent on the number of lesi ns, with eyes with multifocal lesions 
being at a higher risk.6 Fundus Autofluorescence (FAF) is currently the main imaging 
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atrophy and to document growth over time.9 However FAF is not the best choice for 
delineating foveal sparing (FS) in patients with GA, mainly because of interference of the 
macular pigment which attenuates the FAF signal. Therefore, functional assessment and 
spectral-domain ocular coherence tomography (SD-OCT) is better suited to identify FS.10 
Fluorescence lifetime imaging ophthalmoscopy (FLIO) enables a two-dimensional 
topographical mapping of fluorescence lifetimes of the retina in-vivo.11, 12 With this 
technique, metabolic or pathologic processes of the retina can be better portrayed.13 FLIO is 
able to detect early changes in various retinal diseases, such as Stargardt disease14, 
hydroxychloroquine-retinopathy15 or macular-telangiectasia type 2.16 The FLIO signal has 
been shown to be strongly influenced by macular pigment17, which leads to shortening of 
fluorescence lifetimes.18 GA was specifically investigated with FLIO in 2016 by Dysli et 
al.14, 19and in 2018 by Sauer et al.20 In these studies a better BCVA correlated significantly 
with foveal fluorescence lifetimes (fFLT). Furthermore, foveal sparing (FS) was associated 
with shorter fFLT. Therefore, declining visual function and/or loss of foveal sparing due to 
atrophy extending towards the fovea should be accompanied by increasing fFLT. However, it 
was observed that short fFLT are not an exclusive feature of eyes with FS19. It can be 
hypothesized, that these eyes might be at the turnove  point of losing their FS status, which is 
already showing through diminishing visual performance, while still displaying shorter fFLT. 
Another possibility is that these eyes represent a subcategory where short fluorescence 
lifetimes are preserved even in presence of atrophy. T e goal of this study was to evaluate 
longitudinal changes of fFLT in patients with and without FS in GA due to dry AMD, to 
describe temporal changes in fFLT and to investigate c ses of persisting short fFLT in eyes 
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The registration for this study can be found at ClinicalTrials.gov under NCT01981148. 
Written informed consent was obtained from all participants before study enrollment. All 
procedures used in this study adhered to the tenets of the Declaration of Helsinki and the 
International Ethical Guidelines for Biomedical Research involving Human Subjects 
(Council for International Organizations of Medical Sciences). They were approved by the 
local Ethics Committee of the University of Bern, Switzerland. 
 
Patients 
Patients were recruited from the outpatient departmen  of ophthalmology at the Inselspital, 
University Hospital of Bern in Switzerland. Patients with GA secondary to dry AMD were 
included. Patients with signs of neovascular AMD and progressing cataract were excluded. 
None of the included patients exhibited further ocular pathologies, which could have a 
significant influence on measured BCVA. For further analysis a pseudophakic subgroup was 
formed. The clinical characteristics of the complete cohort and the pseudophakic subgroup 
can be found in Table 1. None of the included participants took carotenoid supplementations. 
Geographic atrophy was defined by areas of decreased retinal pigmentation in fundoscopy 
and decreased autofluorescence with sharply demarcated borders in FAF images with 
complete retinal pigment epithelium (RPE) and outer retinal atrophy (cRORA) depicted by 
spectral-domain OCT (as defined by the consensus definition for atrophy associated with 
AMD on OCT21). Foveal sparing was defined by isles of intact outer retinal layers and retinal 
pigment epithelium in the central foveal area in spectral-domain OCT images. Eyes were 
divided into a group with foveal sparing and a group without according to the OCT findings. 
The group without foveal sparing was further subdivided into two subgroups: one with 
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separating the two subgroups was set at a fFLT of 600 picoseconds (ps) measured in the short 
spectral channel (SSC). 
 
Examinations 
All patients were examined at a baseline and a follow-up visit by an ophthalmologist.  
Examinations consisted of best corrected distance visual acuity (BCVA, with Early 
Treatment Diabetic Retinopathy Study (ETDRS22) letters) testing and a slit lamp and dilated 
fundus examination. Multimodal imaging consisted of spectral-domain OCT and blue-light 
FAF using a Heidelberg Spectralis HRA+OCT (Heidelberg Engineering, Heidelberg, 
Germany) and Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO). In addition, Macular 
Pigment Optical Density (MPOD) measurements were obtained for all patients at the follow-
up visit using dual wavelength autofluorescence (Heidelberg Engineering MultiColor 
Spectralis Module, Heidelberg, Germany). Additionally the optical density of macular 
pigment was acquired at 0.5° and 2° eccentricity at the follow-up visit. More peripheral 
eccentricities were not considered as this would lea to inclusion of atrophic areas with zero-
line or negative optical density readings. The outer reference point was set at 9° eccentricity, 
which allowed the measurement of reliable macular pigment data in previous studies.23, 24 
 
FLIO Measurement 
Fluorescence lifetimes (FLT) of the retina were acquired using a prototype fluorescence 
lifetime imaging ophthalmoscope (FLIO) device from Heidelberg Engineering.  
The FLIO device radiates with a 473 nm pulsed blue laser at 80 MHz repetition rate for 
excitation of retinal autofluorescence. The emitted fluorescence is registered by time-
correlated single-photon counting (TPSPC) modules using two highly sensitive hybrid 
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with distinct wavelengths ranges were used. A short spectral channel (SSC, 498–560 nm) and 
a long spectral channel (LSC, 560–720 nm) as displayed in Figure 1. A confocal high-
contrast infrared image was recorded simultaneously to ensure that each recorded photon is 
localized at the correct spatial location. A photon count of 1000 photons per pixel was 
acquired at least for every location within the image. FLIO image acquisition took 
approximately 1.5 to 3 minutes per eye. 
 
Analysis of Fluorescence Lifetime Data  
The Becker&Hickl software (SPCImage 4.4.2) was used for the analysis of recorded lifetime 
data. A biexponential decay model was applied using a binning factor of one. This procedure 
resulted in a short (T1) and a long (T2) lifetime component with corresponding amplitudes a1 
and a2. 
For topographical mapping and quantitative analysis of measured fluorescence lifetimes, the 
software “FLIO Reader” (ARTORG Center for Biomedical Engineering Research, University 
of Bern, Bern, Switzerland) was used. Foveal fluorescence lifetimes (fFLT) were measured, 
using a circular measurement area with a diameter of 100 μm within the central foveal area 
(defined by a circular area with the central point of he foveola and a diameter of 300 μm). 
Mean fluorescence lifetime (Tm) as well as the individual components T1 and T2 and 
amplitudes a1 and a2 were recorded for each region of interest. Tm represents an amplitude-
weighted average of the decay parameters T1 and T2. 
 
Statistical analysis 
For statistical analysis the software Prism 8 (GraphPad Software Inc., La Jolla, CA, USA) 
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omnibus K2 test. Pearson correlation and one-way ANOVA with a multiple-comparison test 
was used. P-values of ≤0.05 were considered as statistically significant. 
 
Results: 
Thirty three eyes of 19 patients were included. 11 patients were female, 8 were male. The 
mean age of all patients was 77.9 years at baseline and 82.8 years at follow-up. Ten eyes 
(30%) exhibited foveal sparing (FS) at baseline. Of these 10 eyes, 6 exhibited persisting FS at 
follow-up. In the pseudophakic subgroup 19 eyes of 12 patients were analyzed. An overview 
of the complete cohort and the pseudophakic subgroup is listed in Table 1. 
 
Best Corrected Visual Acuity (BCVA) 
The decrease in BCVA per year (mean ± Standard Error of the Mean “SEM”) of the entire 
cohort was -1.64 ±0.38 letters. The yearly decrease of BCVA in the pseudophakic cohort was 
similar with -1.46 ±0.42 letters (Figure 2).  All BCVA results for the the complete and 
pseudophakic cohort and their subgroups are summarized in Table 1, 2 and 3. 
 
Foveal Fluorescence Lifetimes (fFLT) 
The fFLT increased yearly by an average (±SEM) of 47 ±17 ps in the SSC and 29 ±10 ps in 
the LSC (in the complete cohort) and by 32 ±11 ps in the SSC and 24 ±9 ps in the LSC in the 
pseudophakic subgroup (Figure 2). In pseudophakic eyes with FS, the fFLT prolonged yearly 
by (mean ±SEM) 39 ±11 ps in the SSC and by 30 ±13 ps in the LSC (Figure 3, left column). 
In the group with persisting FS at follow-up, the fFLT prolonged yearly by 32 ±7 ps in the 
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In comparison, in the group without FS the fFLT prolonged each year by 29 ±15 ps in the 
SSC and by 22 ±13 ps in the LSC (Figure 3, right column). FLT data for each group is 
displayed in Table 1, 2 and 3. 
Correlating the BCVA of all eyes with the corresponding fFLT showed a significant 
correlation for both spectral channels at baseline (SSC p=0.018 and LSC p=0.005) and at 
follow-up (SSC p=0.0355 and LSC p=0.0066). In the ps udophakic group no significant 
correlations at baseline and follow-up were noted (SSC p=0.11 and LSC p=0.17 at baseline 
and SSC p=0.13 and LSC p=0.17 at follow-up). The correlation between the mean 
prolongation in fFLT and mean decrease in BCVA between baseline and follow-up was 
significant for the complete cohort in the LSC with p=0.02 (SSC p=0.7).   
 
Macular Pigment Optical Density (MPOD) 
The MPOD value for the follow-up visit at 0.5° eccentricity was 93 ±36 auc (mean ±SEM; 
auc: area under the curve) and at 2° it was 814 ±396 auc. In the pseudophakic subgroup it 
was 136 ±59 auc  at 0.5° and 1272 ±627 auc at 2° respectively. 
Correlating the MPOD values of all eyes with the respective fFLT showed a significant 
correlation at 0.5° (SSC p=0.046 and LSC p=0.018) and t 2° (SSC p=0.077 and LSC 
p=0.034) 
In the pseudophakic group no significant correlation was noted (SSC p=0.081 and LSC 
p=0.084 at 0.5° and SSC p=0.015 and LSC p=0.16 at 2°). 
 
Discussion: 
A previous study, which examined foveal sparing with FLIO, showed that large FLT 
differences between the fovea and the surrounding atrophic areas correlate with better visual 










 Copyright © 20 The Author(s). Published by Wolters Kluwer Health, Inc.2




exhibits shorter lifetimes with the shortest lifetimes measured in the fovea. This points 
towards a strong association of short retinal lifetim s with good visual acuity. 
However, a big difference in FLT between the foveal area and surrounding atrophic areas or 
even simply short fFLT does not seem to reliably predict cases of FS. In our cohort about half 
of the patients without FS exhibited persisting, relatively short fFLT features (<600 ps in the 
SSC). The mean fFLT of these eyes in the pseudophakic subgroup was 354 ps (SSC), which 
may not be very short in comparison to the mean fFLT of 181 ps (SSC) of the eyes with FS, 
though there were individual cases in the No FS/short fFLT subgroup with a very short fFLT 
comparable to cases with FS, the shortest being 105 ps (see Figure 4, in which the eye with 
FS and the eye without FS but short lifetimes exhibits roughly the same fFLT). The yearly 
decrease in BCVA of -2.1 letters of these eyes with shorter fFLT features was more 
pronounced compared to eyes with fFLT >600ps where the decrease was -0.9 letters (Table 
3). This is an indication that non FS eyes with shorter fFLT might be in an intermediary state 
of foveal atrophy, in which the functionality (BCVA) is already severely diminished but 
structural components responsible for the short fFLT are not yet totally degraded and that 
these two subgroups do not represent two different disease entities. Furthermore this confirms 
that short fFLT should not be used as a surrogate mrker for visual acuity in these cases. 
 
While various retinal components display short fluorescence decay lifetimes, specifically 
macular pigment (MP) correlated favorably with good visual function in AMD.25 It is 
presumed that MP contributes a large part of the short fFLT in FLIO measurements. The 
typical distribution of lifetimes in FLIO, with the shortest FLT observed in the foveal region, 
is presumed to be highly correlated with the distribution of macular pigment.17 MP can be 
measured using dual wavelength autofluorescence.23 It has to be noted, that the measurement 
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standard deviations or partly resulting in negative readings. However, we decided to include 
this measurement to have an additional reference point available and to support the 
hypothesis that macular pigment can be preserved in yes with non FS in geographic atrophy. 
We measured MPOD in the central 0.5° and 2° area to compare it to our measured fFLT. MP 
and FLT parameters showed to correlate significantly i  a previous study18. This is in keeping 
with our data. 
 
We verified all cases of FS by analyzing the respectiv  OCT images. Patients with foveal 
sparing exhibited central isles of intact RPE and outer retinal layers, whereas in eyes without 
sparing RPE was absent and the photoreceptor layers were completely eradicated or severely 
disorganized (Figure 4). When comparing the OCTs of the individual subgroups, no 
significant differences were noticed, which could explain the observed differences in fFLT. 
One theoretically possible explanation would be that cells storing macular pigment are still 
present in these cases, though their function might be severely impaired or their remains are 
not yet cleared from the tissue. However, this hypothesis could not be objectively evaluated 
on basis of the OCT scans. 
 
Limitations 
One of the main limitations of our study is the number of patients, especially of those with 
foveal sparing. This can be largely explained by the longitudinal nature of the study, the 
relative new and scarcely deployed imaging technique used as well as the advanced age of 
the typical patient with GA. A confounding bias might have been introduced by partly using 
both eyes for the measurements and analysis. However, disease progression shows a low 
concordance between the two eyes of the same patient concerning BCVA; and only 
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previous study.26 Another limitation represents the inclusion of MPOD measurement in eyes 
affected by geographic atrophy. In cases of significant GA, measurements can return zero 
line or even negative optical density reading with a big standard deviation and are generally 
unreliable. Nevertheless, we decided to include these measurements as we only measured the 
central 0.5° and 2°, which were often free from gross atrophy. Furthermore, this 
measurement represents the only method for measuring abundance of macular pigment, 
which was shown to correlate with visual acuity. 
 
Conclusion: 
Foveal sparing in eyes with GA due to dry AMD is asociated with shorter foveal 
fluorescence lifetimes (fFLT) compared to eyes with GA and no foveal sparing. A major 
finding is that short fFLT may be retained even in eyes with no foveal sparing. While higher 
BCVA was reported to correlate with shorter fFLT and thereby indirectly indicating a 
functioning central retinal metabolism, this correlation is not valid for these cases. They seem 
to represent eyes with a slower degradation of short FLT emitting components, e.g. retained 
macular pigment. Furthermore, they do not seem to represent a different disease entity, but 
more so an earlier stage of disease, as they show a faster decline in BCVA and more 
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Fig 1 Representative images of Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO) and 
corresponding Fundus Autofluorescence (FAF) measurements as well as Optical Coherence 
Tomography (OCT) with a horizontal cut through the fovea (white dotted line in the FAF 
image) for the baseline and follow-up visit for one eye. In this individual patient foveal 
sparing persisted and foveal fluorescence lifetimes stayed short. SSC: Short Spectral 
Channel, LSC: Long Spectral Channel 
 
 
Fig 2 Two graphs representing the decrease of Best Corrected Visual Acuity (BCVA, top 
row) and the increase of foveal fluorescence lifetim s (foveal FLT, bottom row) in the 
complete cohort (left column) and the pseudophakic group (right column). Eyes with and 
without foveal sparing were included. SSC: Short Spectral Channel, LSC: Long Spectral 
Channel, ps: picoseconds. 
 
Fig 3 Representative Fluorescence Lifetime (FLIO) images of an eye with foveal sparing and 
one without at baseline and follow-up. On the graphs the Best Corrected Visual Acuity 
(BCVA) measured in ETDRS letters and the foveal Fluorescence Lifetimes for the short and 
long spectral channel (SSC and LSC respectively) of the pseudophakic subgroup are drawn. 
 
Fig 4 Representative images of three eyes with different foveal fluorescence lifetimes (FLT) 
presentation. In the left column an eye with foveal sparing is shown. In the middle column, 
an example with persisting short foveal FLT but no clear foveal sparing in OCT and FAF, 
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prolonged foveal FLT is depicted. FLIO: Fluorescence Lifetime Imaging Ophthalmoscopy, 
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Table 1 Overview of characteristics* of the complete cohort and the pseudophakic 
subgroup. 
 
Complete Cohort Baseline Follow-up 
age 77.9 (66 – 90) years 82.4 (70 – 95) years 
gender 11 female / 8 male (n=19) 
BCVA 45.5 Letters (≈20/125) 36.9 Letters (≈20/200) 
BCVA change -1.64 ±0.38 Letters / year 
fFLT (SSC) 620 ±72 ps 841 ±100 ps 
fFLT (LSC) 697 ±57 ps 839 ±69 ps 
fFLT change (SSC) +47 ±17 ps / year 
fFLT change (LSC) +29 ±10 ps / year 





age 79.6 (71 – 90) years 84.5 (75 – 95) years 
gender 7 female / 5 male (n=11) 
BCVA 46.7 Letters (≈20/125) 39.6 Letters (≈20/160) 
BCVA change -1.46 ± 0.42 Letters / year 
fFLT (SSC) 456 ±78 ps 613 ±87 ps 
fFLT (LSC) 578 ±69 ps 699 ±72 ps 
fFLT change (SSC) +32 ±11 ps / year 
fFLT change (LSC) +24 ±9 ps / year 
Foveal Sparing 6 eyes 4 eyes 
 
* Expressed in mean values ±Standard Error of the Mean (SEM) for fFLT and range for age. 
BCVA: Best Corrected Visual Acuity in ETDRS letters, fFLT: foveal Fluorescence Lifetimes, 
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Table 2 Overview of the foveal sparing and non foveal sparing subgroup of the complete 
cohort and the pseudophakic subgroup. 
 
Complete Cohort Foveal sparing (n=10) No foveal sparing (n=23) 
Age at baseline (range) 76.6 (70 – 84) years 78.3 (66 – 90) years 
BCVA at baseline 74.6 ±2.9 letters 32.8 ±3.2 letters 
BCVA at follow-up 62.6 ±5.6 letters 25.7 ±3.5 letters 
BCVA change -2.1 ±1 letters / year -1.4 ±0.4 letters /year 
fFLT at baseline (SSC) 334 ±90 ps 744 ±85 ps 
fFLT at follow-up (SSC) 630 ±196 ps 933 ±113 ps 
fFLT at baseline (LSC) 432 ±43 ps 812 ±67 ps  
fFLT at follow-up (LSC) 620 ±94 ps 934 ±83 ps 
fFLT change (SSC) +62 ±35 ps / year +40 ±20 ps / year 




Foveal sparing (n=6) No foveal sparing (n=13) 
Age at baseline (range) 76.5 (72 – 83) years 81.1 (71 – 90) years 
BCVA at baseline 73.5 ±4.7 letters 34.3 ±3.7 letters 
BCVA at follow-up 67 ±4.9 letters 27 ±5.3 letters 
BCVA change -1.35 ±1 letters / year -1.5 ±0.5 letters / year 
fFLT at baseline (SSC) 181 ±24 ps 583 ±95 ps 
fFLT at follow-up (SSC) 368 ±64 ps 726 ±112 ps 
fFLT at baseline (LSC) 264 ±38 ps 681 ±81 ps 
fFLT at follow-up (LSC) 496 ±55 ps 793 ±92 ps 
fFLT change (SSC) +39 ±11 ps / year +29 ±15 ps / year 
fFLT change (LSC) +30 ±13 ps / year +22 ±13 ps / year 
 
Values expressed in mean ±Standard Error of the Mean (SEM) for BCVA, fFLT and range for 
age. BCVA: Best Corrected Visual Acuity in ETDRS letters, fFLT: foveal Fluorescence 
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Values expressed in mean ±Standard Error of the Mean (SEM) for BCVA, fFLT and range for 
age. BCVA: Best Corrected Visual Acuity in ETDRS letters, ±: Standard Error of the Mean 
(SEM); fFLT: foveal Fluorescence Lifetimes, SSC: Short Spectral Channel, LSC: Long Spectral 
Channel, ps: Picoseconds 
Complete Cohort No foveal sparing / short fFLT 
(<600 ps) (n=10) 
No foveal sparing / long fFLT 
(>600 ps) (n=13) 
Age at baseline (range) 81.9 (71 – 90) years 75.5 (66 – 84) 
BCVA change -2.1 ±0.53 letters / year -0.9 ±0.45 letters / year 
fFLT (SSC) at  baseline 371 ±53 ps 1033 ±76 ps 
fFLT (SSC) at  follow-up 527 ±77 ps (+42%) 1245 ±138 ps (+21%) 
fFLT (LSC) at  baseline 513 ±59 ps 1042 ±51 ps 
fFLT (LSC) at  follow-up 654 ±78 ps (+27%) 1150 ±101 ps (+10%) 
fFLT change (SSC) +30 ±9 ps / year +47 ±35 ps / year 










 Copyright © 20 The Author(s). Published by Wolters Kluwer Health, Inc.2












 Copyright © 20 The Author(s). Published by Wolters Kluwer Health, Inc.2












 Copyright © 20 The Author(s). Published by Wolters Kluwer Health, Inc.2












 Copyright © 20 The Author(s). Published by Wolters Kluwer Health, Inc.2












 Copyright © 20 The Author(s). Published by Wolters Kluwer Health, Inc.2
on behalf of the Ophthalmic Communications Society, Inc.
1
